Key Details
Price
$14.00Annual Revenue
$753.20 MAnnual EPS
-$3.18Annual ROE
-31.55%Beta
1.09Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 26, 2009Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today provided an update on its engagement with UnitedHealthcare (UNH) following the Nov 1, 2024 publication of its updated medical policy restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. Since the announcement, Myriad has actively engaged in constructive dialogue with UNH regarding the clinical evidence supporting Myriad's proprietary and clinically differentiated mental health medication test, GeneSight, including presenting additional clinical data to UnitedHealthcare for its further review and consideration.
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.
Myriad Genetics' Prolaris test reinforced as an 'Advanced Tool' by the NCCN for prognostic assessment.
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries.
Myriad Genetics incorporates its proprietary HRD platform in Illumina's updated TruSight Oncology 500 v2 comprehensive gene panel assay.
NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. On October 31, 2024, it was revealed that UnitedHealth Group ("UnitedHealth") would no longer cover GeneSight, Myriad's genetic test to help determine which mental health medications are likely to work with an individual patient, beginning January 1, 2025.
FAQ
- What is the primary business of Myriad Genetics?
- What is the ticker symbol for Myriad Genetics?
- Does Myriad Genetics pay dividends?
- What sector is Myriad Genetics in?
- What industry is Myriad Genetics in?
- What country is Myriad Genetics based in?
- When did Myriad Genetics go public?
- Is Myriad Genetics in the S&P 500?
- Is Myriad Genetics in the NASDAQ 100?
- Is Myriad Genetics in the Dow Jones?
- When was Myriad Genetics's last earnings report?
- When does Myriad Genetics report earnings?
- Should I buy Myriad Genetics stock now?